

THE CLEAREST IMAGES ON THE LARGEST SCREENS

FILMS TO THE FULLEST

# Second Quarter 2020 **Financial Results**

July 28, 2020

#### **Forward-Looking Statements**

This presentation contains forward looking statements that are based on IMAX<sup>®</sup> management's assumptions and existing information and involve certain risks and uncertainties which could cause actual results to differ materially from future results expressed or implied by such forward looking statements. Important factors that could affect these statements include, but are not limited to, references to future capital expenditures (including the amount and nature thereof), business and technology strategies and measures to implement strategies, competitive strengths, goals, expansion and growth of business, operations and technology, plans and references to the future success of IMAX Corporation together with its consolidated subsidiaries (the "Company") and expectations regarding the Company's future operating, financial and technological results.


These forward-looking statements are based on certain assumptions and analyses made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors it believes are appropriate in the circumstances. However, whether actual results and developments will conform with the expectations and predictions of the Company is subject to a number of risks and uncertainties, including, but not limited to, risks associated with investments and operations in foreign jurisdictions and any future international expansion, including those related to economic, political and regulatory policies of local governments and laws and policies of the United States and Canada; risks related to the Company's growth and operations in China; the performance of IMAX DMR® films; the signing of theater system agreements; conditions, changes and developments in the commercial exhibition industry; risks related to currency fluctuations; the potential impact of increased competition in the markets within which the Company operates; competitive actions by other companies; the failure to respond to change and advancements in digital technology; risks relating to recent consolidation among commercial exhibitors and studios; risks related to new business initiatives; conditions in the in-home and out-of-home entertainment industries; the opportunities (or lack thereof) that may be presented to and pursued by the Company; risks related to cyber-security and data privacy; risks related to the Company's intellectual property; general economic, market or business conditions; the failure to convert theater system backlog into revenue; changes in laws or regulations; the failure to fully realize the projected cost savings and benefits from any of the Company's restructuring initiatives; the impact of COVID-19 on our financial condition and results of operations and on the businesses of our customers and exhibitor partners; and other factors, many of which are beyo

# Strategic Update

### Richard Gelfond Chief Executive Officer



#### **Investment Highlights**



IMAX is focused on reopening China, other select markets, and film slate planning with studios

Source: Company Data



### The IMAX Ecosystem

Deeply Embedded in the Fabric of the Global Entertainment Industry

Filmmakers Cameras Pre / Post Production Aspect Ratio **Eventicize Content** Consumers The IMAX Experience® **Eventicize Content** IMAX Exhibitors Marketing **Eventicize Content Drive Pricing** Drive Volume


Creatives/

#### **Studios**

DMR Marketing Eventicize Content Post-Production

Streamers

**Eventicize Content** 



### IMAX is a Global Brand; Network & Backlog Grow


Diversified global network of 1,527 screens positioned to benefit from rolling openings

#### **1,527 Commercial Theatres in 81 Countries and Territories**



6

#### **Reopening Progress**



<sup>(1)</sup> Theater counts reflect total # of theaters that contributed to respective monthly GBO

Network coming back on line with reopening of China, Europe, and Asia



July MTD



#### Partner Demand for *The* IMAX *Experience*

- 29 IMAX systems signed in Q2 2020 despite theater closures
  - CGV: 17 theaters, hybrid deals, limited capex
  - Wanda: 10 new locations, JV deals<sup>1</sup>
- Backlog growth of 26 systems to a total of 559
- IMAX is seeing continued demand for theater systems
  - Existing operators expanding IMAX capacity
  - Demand for systems in existing and new markets
- Installations of IMAX Theater Systems accelerated in July

<sup>1</sup> Wanda signed a 10-system laser upgrade in Q1, and expanded the agreement in Q2 to include 10 new IMAX locations

Our partners continue to choose to grow with IMAX



### **Consumer Demand for Moviegoing and The IMAX Experience**

#### Moviegoing

#### China

- Shanghai Film Festival sold 120K tickets in an hour -
- 3.2 million attendees weekend of July 24<sup>th</sup> -
- Per screen average attendance at 80% pre-COVID levels -
- France
  - 3 million admissions in first three weeks
- Korea
  - *Peninsula* generated \$26.5 million GBO
- Czech Republic
  - Success reopening theater with primarily local language -

content

### The IMAX Experience

- China
  - Dolittle & Bloodshot \$750K weekend GBO
- Japan
  - The Dark Knight Trilogy
  - \$1 million box office in Japan showing Akira
- Korea
  - Peninsula: first \$1 million post-COVID weekend
  - 50% of national GBO showing: *Avengers* and *The Dark* 
    - *Night* trilogy
- Netherlands:
  - sold-out 30 showings of Interstellar

#### Clear consumer desire to return to theaters across the world

Source: Company Data

#### **IMAX in Recovery**

#### **Recession Resistant**

- Inexpensive, out of home entertainment
  - Viewed as an affordable luxury
- Historical U.S Box Office in recessions:
  - 2009: +10% -
  - 2008: -0.3% -
  - 2002: +13%
  - 2001: +8% -

#### **Low Cost Opening**

- IMAX openings should be low risk
  - Limited fixed costs that need scaling
- IMAX can be profitable at limited capacity
- Theater openings likely to include:
  - Discounted tickets
  - Capacity constraints for social distancing
  - Library content to build traffic -

- Slate changes validate theatrical window
- Pent-up demand for out of home entertainment
  - Moviegoing likely to resume before concerts & sporting events
- All blockbuster movies rescheduled
- Backlog of marquee titles
- "Blockbusterization" is good for IMAX

IMAX is well positioned to ramp-up quickly as theaters continue to re-open

#### **Content Pipeline**

Source: Box Office Mojo

### **Expected Second Half 2020 Content Slate**



TENET O

WARE STUDIOS

Black Widow 🚺



Mulan <sup>(1)</sup>



The King's Man

D

U





Detective 🖸 **Chinatown 3** 



to Die

(1) Disney has delayed the release of Mulan; IMAX continues to expect it will release in the second half of 2020

Strong content schedule slated for second half; IMAX DNA and box office re-opening potential to drive demand



Indicates IMAX DNA 11 \*Release schedule contingent on studio scheduling

#### **Expected Blockbuster 2021 Around the Corner**




**Strong pipeline of tentpole releases throughout 2021** 

\*Release schedule contingent on studio scheduling

12

#### **IMAX Market Position**



IMAX is positioned at the nexus of positive industry trends and protected from industry headwinds

#### **Insulated from Industry Risks**

Theatrical window generates value for blockbusters All blockbusters rescheduled during pandemic

- Theatrical window compression will not impact IMAX Core constituency is super fan-boys and fan-girls
- Industry consolidation unlikely to impact IMAX
- 80 to 90% of IMAX's North American box office is generated in

## **Financial Review**

### Patrick McClymont Chief Financial Officer



### **Balance Sheet & Liquidity**

\$ in millions

	As of June 30, 2020
Cash & Cash Equivalents	
Cash & Cash Equivalents in PRC	\$61.5
Revolver Facility (Due June 2023) <sup>1</sup>	
Facility Utilized	\$300.0
IMAX China Credit Facility	
Facility Utilized	\$0.2
Total Available Liquidity	

- IMAX estimates less than \$10 million per month in estimated cash burn in zero-revenue environment
- Covenant flexibility through Q3 2021
- IMAX China repurchased a total of 425.8 thousand shares in Q2 2020 at an average price of US \$1.50, totaling approximately US \$640 thousand.

<sup>1</sup> Does not include uncommitted accordion feature which would allow Company to expand borrowing capacity to a total of \$350 million, subject to certain conditions.

<sup>2</sup> Excludes the impact of deferred financing fees.

Strong balance sheet provides flexibility; key point of differentiation of our model



Source: Company Data

#### **Credit Agreement Amendment**

- Senior secured net leverage ratio covenant suspended through Q1 2021
- Incremental covenant flexibility through Q3 2021
- \$75 million minimum monthly liquidity covenant
- Restricted in making certain payments, such as dividends & share repurchases
- IMAX has the ability to revert to original credit agreement terms at its option

In Q2 and Q3 of 2021, IMAX can substitute Q3 & Q4 2019 EBITDA in place of actual 2020 EBITDA to satisfy the 3.25x senior secured net leverage ratio covenant

Executed credit agreement amendment to provide covenant flexibility through Q3 2021



#### **Financial Performance**

#### **Q2 Result Drivers:**

#### **Revenue impacts**

- Substantially all of our global theater network closed in Q2
- IMAX Technology Network and Maintenance revenue essentially zero

#### **Cost impacts**

- Benefited from cost actions taken early in the year and lower business activity driven by COVID-19 pandemic
- Accrued \$3.2 million in COVID-19 related government benefits which reduced costs

\$ in millions, except per share	<u>YoY</u>	<u>Q2 2020</u>	<u>Q2 2019</u>
Revenue	Ŧ	\$8.9	\$104.8
Global Box Office	÷	\$2.7	\$364.9
Global Commercial Theatre Network	+	1,527	1,445
Gross Margin / (Loss) (\$)	ŧ	(\$7.7)	\$59.6
Gross Profit Margin (%)	÷	(87%)	57%
GAAP Net (Loss) Income	ŧ	(\$30.0)	\$13.8
EPS	¥	(\$0.44)	\$0.19
Net (Loss) Income <sup>1</sup>	ŧ	(\$26.0)	\$11.4
Adj. EPS <sup>1</sup>	÷	(\$0.44)	\$0.32
Adj. EBITDA (\$) <sup>1</sup>	¥	(\$18.5)	\$41.4
Adj. EBITDA Margin (%) <sup>1</sup>	÷	N/A	39.5%

<sup>1</sup> Attributable to common shareholders.

See appendix for reconciliation and definition of non-GAAP financial results.


#### **Financial results driven by Coronavirus theater closures**

Source: Company Data

#### **SG&A Items**


#### **Items Impacting SG&A Comparability**

- Cost Reductions: SG&A declined due to cost actions taken in Q1 and lower expenses associated with COVID-19 related reduced business activity
- COVID-19 Relief: \$2.9 million in wage subsidies and payroll tax credits from the Canadian and US governments
- Labor and overhead: lower allocations out of SG&A to COGS and certain other assets



#### SG&A impacted by COVID-19 related items in Q2

#### **Capex Breakdown – Growth vs. Maintenance**



Growth Capex = Investment in joint revenue sharing equipment

JV Upgrade Capex = investment in upgrade of existing joint revenue sharing equipment

Maintenance Capex = Purchase of property, plant and equipment

Flexible financial model with low maintenance capex requirements; capex driven by network growth










### **Network Update – IMAX Systems Pipeline**



#### Backlog grew by 26 systems despite the global closure of theaters; IMAX partners choose to grow with IMAX



#### Source: Company Data



# Appendix

all states and a state of the s

The second second



### **Use of Non-GAAP Financial Measures**

In this earnings presentation, the Company presents adjusted net (loss) income attributable to common shareholders and adjusted net (loss) income attributable to common shareholders per diluted share, EBITDA, Adjusted EBITDA per Credit Facility, Adjusted EBITDA margin and free cash flow as supplemental measures of the Company's performance, which are not recognized under U.S. GAAP. Adjusted net (loss) income attributable to common shareholders and adjusted net (loss) income attributable to common shareholders and adjusted net (loss) income attributable to common shareholders and adjusted net (loss) income attributable to common shareholders and adjusted net (loss) income attributable to common shareholders and adjusted net (loss) income attributable to common shareholders and adjusted net (loss) income attributable to common shareholders and adjusted net (loss) income attributable to common shareholders and adjusted net (loss) income attributable to common shareholders and adjusted net (loss) income attributable to common shareholders and adjusted net (loss) income attributable to common shareholders and adjusted net (loss) income attributable to common shareholders and adjusted net (loss) income attributable to common shareholders and adjusted net (loss) income attributable to common shareholders and adjusted net (loss) income attributable to common shareholders and adjusted net (loss) income attributable to common shareholders and adjusted net (loss) income attributable to common shareholders and adjusted net (loss) income attributable to common shareholders and adjusted net (loss) income attributable to common shareholders and adjusted net (loss) income attributable to common shareholders and adjusted net (loss) income attributable to common shareholders and adjusted net (loss) income attributable to common shareholders and adjusted net (loss) income attributable to common shareholders and adjusted net (loss) income attributable to common shareholders, (iii) changes in the fair value of equity investments, (

The Company believes that these non-GAAP financial measures are important supplemental measures that allow management and users of the Company's financial statements to view operating trends and analyze controllable operating performance on a comparable basis between periods without the after-tax impact of share-based compensation and certain unusual items included in net (loss) income attributable to common shareholders. Although share-based compensation is an important aspect of the Company's employee and executive compensation packages, it is a non-cash expense and is excluded from certain internal business performance measures.

In addition to the non-GAAP financial measures discussed above, management also uses "EBITDA," as such term is defined in the Company's credit agreement, and which is referred to herein as "Adjusted EBITDA per Credit Facility." As allowed by the Company's credit agreement, Adjusted EBITDA per Credit Facility includes adjustments in addition to the exclusion of interest, taxes, depreciation and amortization. Accordingly, this non-GAAP financial measure is presented to allow a more comprehensive analysis of the Company's operating performance and to provide additional information with respect to the Company's compliance against its credit agreement requirements in the current period, if applicable. In addition, the Company believes that Adjusted EBITDA per Credit Facility presents relevant and useful information widely used by analysts, investors and other interested parties in the Company's industry to evaluate, assess and benchmark the Company's results.

EBITDA is defined as net (loss) income excluding: (i) interest expense, net of interest income; (ii) income tax (benefit) expense; and (iii) depreciation and amortization, including film asset amortization. Adjusted EBITDA per Credit Facility is defined as EBITDA excluding: (i) share-based and other non-cash compensation; (ii) gain (loss) in fair value of equity investment; (iii) write-downs, net of recoveries, including asset impairments and credit loss expense; and (iv) (gain) loss from equity accounted investments.

These non-GAAP measures may not be comparable to similarly titled amounts reported by other companies. Additionally, the non-GAAP financial measures used by the Company should not be considered as a substitute for, or superior to, the comparable GAAP amounts.

# . . . . . . . .

#### **Primary Reporting Groups**

The Company has the following reportable segments: (i) IMAX DMR; (ii) Joint Revenue Sharing Arrangements; (iii) IMAX Systems, (iv) IMAX Maintenance; (v) Other Theater Business; (vi) New Business Initiatives; (vii) Film Distribution; and (viii) Film Post-production.

The Company organizes its reportable segments into the following four categories, identified by the nature of the product sold or service provided:

IMAX Technology Network, which earns revenue based on contingent box office receipts and includes the IMAX DMR segment and contingent rent from the Joint Revenue Sharing Arrangement ("JRSA") segment;

IMAX Technology Sales and Maintenance, which includes results from the IMAX Systems, IMAX Maintenance and Other Theater Business segments, as well as fixed revenues from the JRSA segment;

New Business Initiatives, which is a segment that includes activities related to the exploration of new lines of business and new initiatives outside of the Company's core business; and

Film Distribution and Post-production, which includes activities related to the distribution of films primarily for the Company's institutional theater partners (through the Film Distribution segment) and the provision of film post-production and quality control services (through the Film Post-production segment).

The Company is presenting information at a disaggregated level to provide more relevant information to readers.

### Q2 2020 Non-GAAP Financial Reconciliation — Adj. Earnings Per Share

\$ in Thousands, Except EPS Data

		Three Months Ended June 30, 2020			Three Months Ended			
					June 30, 2019			
(In thousands of U.S. dollars, except per share amounts)	]	Net Loss	Dil	uted EPS	Ne	et Income	Dil	uted E
Reported net (loss) income attributable to common								
shareholders	\$	(25,967)	\$	(0.44)	\$	11,397	\$	0.
Adjustments <sup>(1)</sup> :								
Share-based compensation		6,168		0.10	\$	6,799		0.
Changes in the fair value of equity securities		(1,413)		(0.02)		3,101		0.
COVID-19 government relief benefits		(3,151)		(0.05)		_		
Tax impact on items listed above		(857)		(0.01)		(1,604)		(0.
Income tax effects related to the removal of the								
indefinitely reinvested assertion on the historical								
earnings of certain subsidiaries		(841)		(0.02)				
Adjusted net (loss) income <sup>(1)</sup>	\$	(26,061)	\$	(0.44)	\$	19,693	\$	0.
Weighted average basic shares outstanding				58,808				61,3
Weighted average diluted shares outstanding				58,808				61,5

EPS
).19
).11
0.05
).03)
1.05)
—
).32
331
507
001

### Q2 2020 Non-GAAP Financial Reconciliation — Adj. EBITDA

\$ in Thousands

(In thousands of U.S. Douars)	Attributable to Non-controlling	
Reported net loss \$ (30,047) \$ (4,080) \$ (25,967) \$ 13,836 \$ 2,4	139	
Add (subtract):		
	187	
	140)	
Depreciation and amortization, including film asset		
amortization 11,930 1,049 10,881 15,593 1,1	177	
EBITDA \$ (27,841) \$ (2,489) \$ (25,352) \$ 34,801 \$ 4,60	563	
Share-based and other non-cash compensation 6,541 299 6,242 7,186 22	228	
(Gain) Loss in fair value of equity investment (2,025) (612) (1,413) 4,544 1,4	443	
Write-downs, including asset		
impairments and credit loss expense 3,843 1,815 2,028 1,169	84	
Loss from equity accounted investments 138	_	
Adjusted EBITDA per Credit Facility \$ (19,482) \$ (987) \$ (18,495) \$ 47,838 \$ 6,4	18	
Revenues attributable to common		
<u>shareholders(2)</u> 8,855 421 8,434 104,797 10,2	216	
Adjusted EBITDA margin attributable to common		
shareholders (220.0%) (234.7%) (219.3%) 45.6% 62	<u>2.8</u> %	

#### June 30, 2019

Attributable to Common Shareholders			
\$	11,397		
	4,121		
	204		
	14,416		
\$	30,138		
	6,958		
	3,101		
	1,085		
	138		
\$	41,420		
	94,581		
	43.8%		

### Q2 2020 Non-GAAP Financial Reconciliation – Free Cash Flow

\$ in Thousands

#### **Three Months Ended**

	June 30, 2020	
Net cash used in operating activities	\$	(26,846)
Net cash used in investing activities		(3,010)
Free cash flow	\$	(29,856)

#### Six Months Ended June 30, 2020 \$ (20,880) (5,723) \$ (26,603)

# FILMS TO THE FULLEST

